Advanced searches left 3/3

Stereotactic Radiosurgery - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 17 August 2022

* If you want to update the article please login/register

Stereotactic Radiosurgery (SRS) as Definitive Management for a Limited Number of Small Cell Lung Cancer (SCLC) Brain Metastasis

To estimate the cognitive decline rate at 3 months, it is best to estimate it at 3 months. At each time point, the objective is to determine cognitive decline rate on each individual cognitive test. To summarize, the overall survival of patients of patients of small cell lung cancer brain metastasis is examined by radiosurgery. As dictated by the magnetic resonance imaging surveillance schedule above, it is difficult to determine incidences of local tumor control in the brain post-treatment. As outlined by the MRI surveillance schedule above, you will be able to report distant tumor control in the brain post-treatment. The conversion from SRS to whole brain radiation therapy took time to the reporter's time. With SRS, you can calculate the incidence of intracranial toxicity of concurrent atezolizumab. To determine the prevalence of systemic and intracranial disease surveillance in those who are receiving atezolizumab and SRS concurrently. I. Cerebral spinal fluid biomarkers. CORRELATIVE OBJECTIVE OBJECTIVE: I. Cerebral spinal fluid biomarkers. Patients with chronic disease can be treated with additional courses of SRS per physician discretion.

Source link: https://clinicaltrials.gov/ct2/show/NCT04516070


A Pilot Study on the Efficacy of Advanced 18F-FDG PET-MRI in Spine Stereotactic Radiosurgery

In spine stereotactical radiosurgery treatment planning, compare to advanced MRI and conventional MRI, determine the therapeutic effectiveness of fludeoxyglucose F-18 positron emission tomography -magnetic resonance imaging. OUTLINE: Patients are fludeoxyglucose F-18 intravenously for over 1 minute, and then undergoing PET-MRI for 1 hour, 30 days before radiation therapy, and 3 to 6 months after radiation therapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT05174026


Single- vs. Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases

This trial is expected to draw almost 130 people; 65 in each arm: Group 1: If you are enrolled in this trial, you will have spine radiosurgery in a single session.

Source link: https://clinicaltrials.gov/ct2/show/NCT04218617


A Phase III Trial of Pre-Operative Stereotactic Radiosurgery (SRS) Versus Post-Operative SRS for Brain Metastases

To investigate the 1 year leptomeningeal disease -free survival rate among patients with surgically resectable metastatic brain lesions randomized to post-operative stereotactic radiosurgery versus pre-operative SRS followed by surgery. Patients with brain metastasis will be screened for local control, distant brain metastasis rate, and overall survival of pre-operative versus post-operative SRS in patients with brain metastasis. To determine the uncertainties involved with using magnetic resonance imaging for radiomics research, we used a combination of patient data and phantom results to compare the validity of various imaging techniques. In patients with brain metastasis, there is no evidence examining the neuro-cognitive, patient reported findings, and health-related quality of life. Patients with chronic disease may require additional SRS if their disease returns after therapy. Patients are scheduled for surgery within 15 days of randomization and standard of care SRS within 30 days. Patients may require additional SRS if disease persists after therapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT03741673


Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

The radiosurgery volumes would closely resemble HDR brachytherapy therapeutic volumes with similar dose limitation goals to nearby normal tissues, and would closely resemble comparable normal tissues. The CyberKnife Robotic Radiosurgery System is a unique radiosurgical device capable of treating tumors in the body noninvasively and with submillimeter precision.

Source link: https://clinicaltrials.gov/ct2/show/NCT00643617


Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases: a Randomized Phase II Clinical Trial

Study Groups: The participant will be randomly assigned to one of two study groups. If an individual is in Group 1, they will get spine radiosurgery in a single large dose. If participant is in Group 2 and receiving spine radiosurgery over three smaller doses, which is standard. Participation in Length of Study Participation: Participants may continue participating in the study as long as the doctor feels it is in their best interest. Participants will no longer be able to participate if the disease makes it worse, if intolerable side effects occur, or if they are unable to follow study directions, or if they are unable to follow study directions. Radiosurgery: According to Radiosurgery, the participant will have spine radiosurgery in either 1 or 3 treatments as described above.

Source link: https://clinicaltrials.gov/ct2/show/NCT03028337


Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma

To treat patients with recurrent or advanced chordoma, it's best to determine the safety profile of nivolumab alone and nivolumab alone and in combination with stereotactic radiosurgery. In combination with stereotactic radiosurgery, we'll determine the toxicity and tolerability of nivolumab alone and nivolumab. To determine growth modulation index on target lesion, it is recommended that growth modulation index be determined. At 6 months, we'll determine progress-free survival and progression-free survival. To determine peripheral blood immune responses during and after treatment, it will be investigated. Patients are admitted to the hospital for nivolumab intravenously over 30 minutes on day 1. ARM II: Patients are given nivolumab as in Arm I.

Source link: https://clinicaltrials.gov/ct2/show/NCT02989636


A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients With Resectable Brain Metastases

As determined by the MD Anderson Symptom Inventory for Brain Tumors, MD Anderson Symptom Inventory for Brain Tumors II - The trajectory of symptom burden in patients treated with pre-resection SRS to the intact lesion is different from those treated to the post-resection surgical cavity. Compare to patients who receive post-resection SRS, it's determined if there is an elevated overall survival OS in patients with resected brain metastases in patients with pre-resection SRS. In patients who receive pre-resection SRS to patients who receive post-resection SRS, the imaging correlate of radiation necrosis is used to determine the prevalence of ARE, the biological correlate of radiation necrosis. When it comes to patients with pre-resection SRS and those receiving post-resection SRS, it is clear that whole brain radiotherapy (WBRT) is taking longer than in patients with pre-resection SRS. According to the Montreal Cognitive Assessment MoCA, the goal of neuro-cognitive function in patients treated with pre-resection SRS to the intact lesion versus those treated to the post-resection surgical cavity. To patients with post-resection SRS, compare rates of nodular meningeal disease in patients who receive pre-resection SRS to patients with post-resection SRS. To patients who receive pre-resection SRS and those who receive post-resection SRS, we're comparing rates of local recurrence in the resection cavity. To patients who receive pre-resection SRS and patients who receive post-resection SRS, we'll examine the incidences of distant brain dysfunction in patients who have pre-resection SRS to patients with post-resection SRS.

Source link: https://clinicaltrials.gov/ct2/show/NCT05438212


Parallel Prospective Observational Cohorts Evaluating Stereotactic Radiosurgery Alone (SRS) and Whole Brain Radiotherapy (WBRT) Plus SRS for Patients With 5 to 30 Brain Metastases

WBRT has been shown to be detrimental in terms of neurocognition and does not improve patient survival when compared to SRS alone, according to studies in patients with limited brain metastases. However, there is a lack of high-quality prospective randomized data on the role of SRS in patients with 5 or more brain metastases to direct therapy. In patients with 5 to 30 brain metastases, this research will prospectively compare SRS alone versus SRS+ WBRT.

Source link: https://clinicaltrials.gov/ct2/show/NCT03775330

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions